Arpi

Arpi Inc. is a South Korean medical AI company based in Seongnam that develops electrocardiogram (ECG) analysis software for clinical use. Its flagship product, ECG Buddy, classifies cardiac rhythm into 11 arrhythmia categories and produces 10 digital biomarker risk scores — including scores for STEMI and hyperkalemia — from a single ECG, presented on one screen and without requiring patient history. The product is certified by South Korea's Ministry of Food and Drug Safety (MFDS) as a Class II medical device.

A second product, ECG Buddy Clinic, targets clinic and outpatient care and screens for conditions that may be asymptomatic, including left ventricular dysfunction and paroxysmal atrial fibrillation, producing five cardiovascular biomarker risk scores. ECG Buddy Clinic is MFDS-certified as a Class III medical device. The company has also described work on additional products named RaySnap and COMA. Arpi describes its focus as accurate, robust and practical clinical AI, and its team includes emergency medicine professors and nurses.

Business model

Arpi supplies AI-based ECG interpretation software as regulated medical devices to hospitals and clinics, with separate products for acute/hospital settings (ECG Buddy) and clinic and outpatient screening (ECG Buddy Clinic).

Traction

The company reports daily use of its product in more than 120 hospitals nationwide, and holds MFDS certification for ECG Buddy (Class II) and ECG Buddy Clinic (Class III).

Latest developments

Both ECG Buddy and ECG Buddy Clinic are marketed as MFDS-certified medical devices, and the company has cited RaySnap and COMA as products in development.